Clinical trial
A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of…
NCT00001298 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00001298 |
|---|---|
| Title | A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction |
| Official title | A Trial of Carboxypeptidase-G2 (CPDG2) and Thymidine for the Management of Patients With Methotrexate Toxicity and Renal Dysfunction |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Kidney Diseases |
| Intervention type | Drug |
| Interventions | carboxypeptidase-G2 |
| Enrollment | 10 |
| Start date | Mar 1, 1992 |
| Completion | Jan 1, 2001 |
| First posted | Dec 10, 2002 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: